Amgen's second-quarter earnings call highlighted several positive factors that are likely to have a short-term positive impact on the stock price. Here are the key points:

- **Strong Financial Performance**: Amgen reported a strong quarter with revenue growth of 4% year-over-year, adjusted operating income increasing by 10%, and adjusted EPS rising by 8%.
- **Product Growth**: The company saw significant growth in key products such as Enbrel, Sensipar, Prolia, XGEVA, and Kyprolis, with new product launches like Repatha, BLINCYTO, and the Neulasta On-body Injector performing well.
- **Guidance Increase**: Amgen raised its 2015 revenue and adjusted EPS guidance, indicating continued confidence in its strategy and performance.
- **Pipeline Progress**: The R&D pipeline showed promising advancements, including the approval of Repatha in Europe, positive data from Kyprolis, and upcoming regulatory submissions for other key products.
- **Financial Health**: The company has a strong balance sheet, with significant cash flow generation and a commitment to returning capital to shareholders through dividends and share repurchases.

Given these factors, the stock is likely to experience a positive impact in the short term.

[1]